The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated ...

The interaction between RNA-binding proteins (RBPs) and circular RNAs (circRNAs) has emerged as a key area of interest in ...

Despite that, the first RNA-targeting therapeutic in the market was launched only five years ago, and the vast majority of ...

In this interview, industry expert Dr. Lohit Khera discusses the evolving role of microRNA in research, diagnostics, and ...

This valuable study provides insights into a key question in comparative neuroanatomy and development. The authors provide evidence of the role for a particular micro-RNA in regulating the development ...

Ph.D., they show that one RNA-binding protein on the cell surface, NPM1, could be a potent, selective target for treating acute myeloid leukemia (AML), as well as solid tumors. AML, a rapidly ...

they show that one RNA-binding protein on the cell surface, NPM1, could be a potent, selective target for treating acute myeloid leukemia (AML), as well as solid tumors. AML, a rapidly progressive ...

Xiang-Qun Hu https://orcid.org/0000-0003-1626-9541 Lawrence D. Longo, MD Center for Perinatal Biology, Department of Basic Sciences, Loma Linda University School of ...

Key applications of GenAI in drug discovery include: Molecule optimization: 5 This can be used to improve target binding and/or specificity and solubility, stability, aggregation, and other ...

Credit: Scripps Research Hangartner believed multiple factors could be at play, including binding location. Antibodies that target the same viral protein can bind to different spots on its surface ...